Candel Therapeutics (CADL) to Release Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL - Get Free Report) is projected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Candel Therapeutics to post earnings of ($0.23) per share for the quarter.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.17). On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Candel Therapeutics Trading Down 2.3 %

Candel Therapeutics stock traded down $0.19 during mid-day trading on Friday, hitting $8.06. The stock had a trading volume of 2,512,356 shares, compared to its average volume of 2,686,195. The stock has a 50-day simple moving average of $8.22 and a two-hundred day simple moving average of $7.02. The stock has a market capitalization of $261.76 million, a PE ratio of -4.66 and a beta of -1.29. Candel Therapeutics has a 12 month low of $1.45 and a 12 month high of $14.60.

Insiders Place Their Bets

In other news, CTO Seshu Tyagarajan sold 31,278 shares of Candel Therapeutics stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $8.82, for a total transaction of $275,871.96. Following the transaction, the chief technology officer now owns 85,512 shares in the company, valued at $754,215.84. The trade was a 26.78 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Francesca Barone sold 13,534 shares of Candel Therapeutics stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $97,715.48. Following the transaction, the insider now owns 110,673 shares in the company, valued at $799,059.06. This trade represents a 10.90 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 77,807 shares of company stock worth $633,534. Insiders own 41.60% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

CADL has been the topic of several recent research reports. Canaccord Genuity Group raised their price target on Candel Therapeutics from $20.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. Bank of America initiated coverage on Candel Therapeutics in a report on Friday, February 7th. They set a "buy" rating and a $15.00 target price on the stock. Citigroup initiated coverage on Candel Therapeutics in a report on Thursday, February 20th. They set a "buy" rating and a $25.00 target price on the stock. Finally, HC Wainwright restated a "buy" rating and set a $19.00 target price on shares of Candel Therapeutics in a report on Friday, March 14th.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.